Summary of Study ST003286

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002038. The data can be accessed directly via it's Project DOI: 10.21228/M85V5Z This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003286
Study TitleInteraction between NSCLC cells, CD8+ T cells and immune checkpoint inhibitors potentiates coagulation and promotes metabolic remodeling- new cues on CAT-VTE
Study SummaryCancer-related thrombosis (CAT) and venous thromboembolism (VTE) are common cancer-related sequelae linked with high mortality, therefore finding predictive indicators is critical. Immune checkpoint inhibitors (ICI) are utilized in cancer immunotherapy to activate T lymphocytes against cancer cells. Recent retrospective investigations found that some individuals experienced increased VTE after receiving ICI. We postulated that ICI (anti-CTLA4 and anti-PD1) effect on immunological and cancer cells, as well as their interaction, contributes for an elevated risk of CAT-VTE. Our objective is to investigate this molecular interaction in order to uncover potential prothrombotic indicators. We pharmacologically modulated non-small cell lung cancer (NSCLC) cell lines in co-culture with CD8+ T lymphocytes (T CD8+) obtained from healthy blood donors. Nuclear Magnetic Resonance (NMR) metabolic remodeling analysis revealed differences in extracellular metabolite concentrations after T CD8+ and ICI treatment.
Institute
ITQB NOVA
Last NameGonçalves
First NameLuís
AddressAvenida Republica
Emaillgafeira@itqb.unl.pt
Phone214469464
Submit Date2023-11-20
Raw Data AvailableYes
Raw Data File Type(s)fid
Analysis Type DetailNMR
Release Date2024-07-03
Release Version1
Luís Gonçalves Luís Gonçalves
https://dx.doi.org/10.21228/M85V5Z
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Cell line Culture Type Immune checkpoint inhibitor
SA356220CD_A549_3_1_IPI3_rep3Non-small cell lung cancer cells A549 Direct Co-culture Ipilimumab
SA356221CD_A549_3_1_IPI3_rep1Non-small cell lung cancer cells A549 Direct Co-culture Ipilimumab
SA356222CD_A549_3_1_IPI3_rep2Non-small cell lung cancer cells A549 Direct Co-culture Ipilimumab
SA356223CD_A549_3_1_NIV3_rep3Non-small cell lung cancer cells A549 Direct Co-culture Nivolumab
SA356224CD_A549_TW_NIV2_rep2Non-small cell lung cancer cells A549 Direct Co-culture Nivolumab
SA356225CD_A549_3_1_NIV3_rep1Non-small cell lung cancer cells A549 Direct Co-culture Nivolumab
SA356226CD_A549_3_1_CTL3_rep3Non-small cell lung cancer cells A549 Direct Co-culture No treatment
SA356227CD_A549_TW_CTL2_rep2Non-small cell lung cancer cells A549 Direct Co-culture No treatment
SA356228CD_A549_3_1_CTL3_rep1Non-small cell lung cancer cells A549 Direct Co-culture No treatment
SA356229CD_A549_TW_IPI3_rep1Non-small cell lung cancer cells A549 Indirect Co-culture Ipilimumab
SA356230CD_A549_TW_IPI3_rep2Non-small cell lung cancer cells A549 Indirect Co-culture Ipilimumab
SA356231CD_A549_TW_IPI3_rep3Non-small cell lung cancer cells A549 Indirect Co-culture Ipilimumab
SA356232CD_A549_NIV2_rep2Non-small cell lung cancer cells A549 Indirect Co-culture Nivolumab
SA356233CD_A549_TW_NIV3_rep3Non-small cell lung cancer cells A549 Indirect Co-culture Nivolumab
SA356234CD_A549_TW_NIV3_rep1Non-small cell lung cancer cells A549 Indirect Co-culture Nivolumab
SA356235CD_A549_TW_CTL3_rep3Non-small cell lung cancer cells A549 Indirect Co-culture No treatment
SA356236CD_A549_CTL2_rep2Non-small cell lung cancer cells A549 Indirect Co-culture No treatment
SA356237CD_A549_TW_CTL3_rep1Non-small cell lung cancer cells A549 Indirect Co-culture No treatment
SA356238CD_A549_IPI3_rep3Non-small cell lung cancer cells A549 Monoculture Ipilimumab
SA356239CD_A549_IPI3_rep2Non-small cell lung cancer cells A549 Monoculture Ipilimumab
SA356240CD_A549_IPI3_rep1Non-small cell lung cancer cells A549 Monoculture Ipilimumab
SA356241CD_A549_NIV3_rep3Non-small cell lung cancer cells A549 Monoculture Nivolumab
SA356242CD_A549_NIV3_rep1Non-small cell lung cancer cells A549 Monoculture Nivolumab
SA356243CD_A549_3_1_NIV2_rep2Non-small cell lung cancer cells A549 Monoculture Nivolumab
SA356244CD_A549_3_1_CTL2_rep2Non-small cell lung cancer cells A549 Monoculture No treatment
SA356245CD_A549_CTL3_rep1Non-small cell lung cancer cells A549 Monoculture No treatment
SA356246CD_A549_CTL3_rep3Non-small cell lung cancer cells A549 Monoculture No treatment
SA356247CD_H292_TW_IPI1_rep2Non-small cell lung cancer cells H292 Direct Co-culture Ipilimumab
SA356248CD_H292_TW_IPI1_rep3Non-small cell lung cancer cells H292 Direct Co-culture Ipilimumab
SA356249CD_H292_TW_IPI1_rep1Non-small cell lung cancer cells H292 Direct Co-culture Ipilimumab
SA356250CD_H292_TW_NIV1_rep3Non-small cell lung cancer cells H292 Direct Co-culture Nivolumab
SA356251CD_H292_TW_NIV1_rep2Non-small cell lung cancer cells H292 Direct Co-culture Nivolumab
SA356252CD_H292_TW_NIV1_rep1Non-small cell lung cancer cells H292 Direct Co-culture Nivolumab
SA356253CD_H292_TW_CTL1_rep3Non-small cell lung cancer cells H292 Direct Co-culture No treatment
SA356254CD_H292_TW_CTL1_rep2Non-small cell lung cancer cells H292 Direct Co-culture No treatment
SA356255CD_H292_TW_CTL1_rep1Non-small cell lung cancer cells H292 Direct Co-culture No treatment
SA356256CD_H292_IPI1_rep3Non-small cell lung cancer cells H292 Indirect Co-culture Ipilimumab
SA356257CD_H292_IPI1_rep2Non-small cell lung cancer cells H292 Indirect Co-culture Ipilimumab
SA356258CD_H292_IPI1_rep1Non-small cell lung cancer cells H292 Indirect Co-culture Ipilimumab
SA356259CD_H292_NIV1_rep3Non-small cell lung cancer cells H292 Indirect Co-culture Nivolumab
SA356260CD_H292_NIV1_rep1Non-small cell lung cancer cells H292 Indirect Co-culture Nivolumab
SA356261CD_H292_NIV1_rep2Non-small cell lung cancer cells H292 Indirect Co-culture Nivolumab
SA356262CD_H292_CTL1_rep3Non-small cell lung cancer cells H292 Indirect Co-culture No treatment
SA356263CD_H292_CTL1_rep2Non-small cell lung cancer cells H292 Indirect Co-culture No treatment
SA356264CD_H292_CTL1_rep1Non-small cell lung cancer cells H292 Indirect Co-culture No treatment
SA356265CD_H292_3_1_IPI1_rep3Non-small cell lung cancer cells H292 Monoculture Ipilimumab
SA356266CD_H292_3_1_IPI1_rep2Non-small cell lung cancer cells H292 Monoculture Ipilimumab
SA356267CD_H292_3_1_IPI1_rep1Non-small cell lung cancer cells H292 Monoculture Ipilimumab
SA356268CD_H292_3_1_NIV1_rep3Non-small cell lung cancer cells H292 Monoculture Nivolumab
SA356269CD_H292_3_1_NIV1_rep2Non-small cell lung cancer cells H292 Monoculture Nivolumab
SA356270CD_H292_3_1_NIV1_rep1Non-small cell lung cancer cells H292 Monoculture Nivolumab
SA356271CD_H292_3_1_CTL1_rep2Non-small cell lung cancer cells H292 Monoculture No treatment
SA356272CD_H292_3_1_CTL1_rep1Non-small cell lung cancer cells H292 Monoculture No treatment
SA356273CD_H292_3_1_CTL1_rep3Non-small cell lung cancer cells H292 Monoculture No treatment
SA356274CD_PC9_3_1_IPI1_rep3Non-small cell lung cancer cells PC-9 Direct Co-culture Ipilimumab
SA356275CD_PC9_3_1_IPI1_rep2Non-small cell lung cancer cells PC-9 Direct Co-culture Ipilimumab
SA356276CD_PC9_3_1_IPI1_rep1Non-small cell lung cancer cells PC-9 Direct Co-culture Ipilimumab
SA356277CD_PC9_NIV1_rep3Non-small cell lung cancer cells PC-9 Direct Co-culture Nivolumab
SA356278CD_PC9_NIV1_rep2Non-small cell lung cancer cells PC-9 Direct Co-culture Nivolumab
SA356279CD_PC9_NIV1_rep1Non-small cell lung cancer cells PC-9 Direct Co-culture Nivolumab
SA356280CD_PC9_CTL1_rep3Non-small cell lung cancer cells PC-9 Direct Co-culture No treatment
SA356281CD_PC9_CTL1_rep2Non-small cell lung cancer cells PC-9 Direct Co-culture No treatment
SA356282CD_PC9_CTL1_rep1Non-small cell lung cancer cells PC-9 Direct Co-culture No treatment
SA356283CD_PC9_TW_IPI1_rep1Non-small cell lung cancer cells PC-9 Indirect Co-culture Ipilimumab
SA356284CD_PC9_TW_IPI1_rep3Non-small cell lung cancer cells PC-9 Indirect Co-culture Ipilimumab
SA356285CD_PC9_TW_IPI1_rep2Non-small cell lung cancer cells PC-9 Indirect Co-culture Ipilimumab
SA356286CD_PC9_TW_NIV1_rep3Non-small cell lung cancer cells PC-9 Indirect Co-culture Nivolumab
SA356287CD_PC9_TW_NIV1_rep2Non-small cell lung cancer cells PC-9 Indirect Co-culture Nivolumab
SA356288CD_PC9_TW_NIV1_rep1Non-small cell lung cancer cells PC-9 Indirect Co-culture Nivolumab
SA356289CD_PC9_TW_CTL3_rep3Non-small cell lung cancer cells PC-9 Indirect Co-culture No treatment
SA356290CD_PC9_TW_CTL3_repNon-small cell lung cancer cells PC-9 Indirect Co-culture No treatment
SA356291CD_PC9_TW_CTL1_rep1Non-small cell lung cancer cells PC-9 Indirect Co-culture No treatment
SA356292CD_PC9_IPI3_rep3Non-small cell lung cancer cells PC-9 Monoculture Ipilimumab
SA356293CD_PC9_IPI3_rep2Non-small cell lung cancer cells PC-9 Monoculture Ipilimumab
SA356294CD_PC9_IPI3_rep1Non-small cell lung cancer cells PC-9 Monoculture Ipilimumab
SA356295CD_PC9_3_1_NIV1_rep3Non-small cell lung cancer cells PC-9 Monoculture Nivolumab
SA356296CD_PC9_3_1_NIV1_rep2Non-small cell lung cancer cells PC-9 Monoculture Nivolumab
SA356297CD_PC9_3_1_NIV1_rep1Non-small cell lung cancer cells PC-9 Monoculture Nivolumab
SA356298CD_PC9_3_1_CTL1_rep2Non-small cell lung cancer cells PC-9 Monoculture No treatment
SA356299CD_PC9_3_1_CTL1_rep3Non-small cell lung cancer cells PC-9 Monoculture No treatment
SA356300CD_PC9_3_1_CTL1_rep1Non-small cell lung cancer cells PC-9 Monoculture No treatment
Showing results 1 to 81 of 81
  logo